Grand Pharmaceutical (HKG:0512) completed the enrollment of patients in its multicenter phase 3 trial for its CBT-001 eye drops, according to a Wednesday filing with the Hong Kong bourse.
The trial will evaluate safety and efficacy of the eye drops in the reduction of conjunctival congestion and pterygium, or a fleshy growth of the conjunctiva, which causes astigmatism or even blindness, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.